G4 Research Grant

Generate high quality next-generation sequencing data for your samples on G4 to propel your scientific explorations and unlock key insights 


Three recipients of the G4 Research Grant will receive sequencing services for up to 4 full runs (16 flow cells*) at up to 2x150bp read lengths with indexing. Recipients will also receive a travel grant to present findings at a conference (up to $25,000 in value).  

Important Dates


Application Opens


Application Closes


Grants Awarded

*1 F3 Flow Cell yields ~400M reads and 1 Max Read flow cell for supported 10x applications yields between 800M-1.2B reads per flow cell depending on application. Visit singulargenomics.com/g4/reagents/ for more information.

Grant Information

Eligibility and Entry

  • Eligible entrants will submit an abstract of up to 300 words along with sample details detailing their proposed project and a copy of their PIs CV.  
  • Applications will be open for submission until March 20th 2024 at 11:59PM PST. 

Project Requirements and Restrictions 

  • Library preparation must be done by award recipients. Singular will provide materials and support for adapting libraries for compatibility on the G4.
  • Samples must be ready by July 1st 2024 and contain no personally identifiable information, personal health information, or Protected Health information. For research use only. Not for diagnostic or clinical use
  • Award must be used in 2024. Award recipients must have access and be able to send samples to Singular Genomics.
  • Award recipients must be willing to release name, institution, title, and project name along with data for use in publication and/or poster submission.
  • Additional restrictions as specified in the Terms & Conditions: Download Here 

Submit G4 Research Grant Application

To apply, please fill out the application form below and upload project details using the template provided before March 20, 2024.

Download Application Template

Drew Spaventa

Drew founded Singular Genomics in 2016 serving as the CEO and Chairman. Drew is a serial entrepreneur and venture investor in the biotech industry and has been involved in the founding of several successful companies. Prior to Singular Genomics, Drew founded Truvian Sciences, a low volume blood testing technology aimed at making routine blood tests easier, less invasive, and more affordable. Drew was also involved in the founding of Aspen Neurosciences where he co-led the seed financing and helped assemble a world-class team to combat Parkinson’s Disease using a patient’s own stem cells. Drew was also a seed investor and held an operating role in Edico Genome which sold to Illumina in 2018.

Drew received an MBA from the Rady School of Management at the University of California, San Diego and a BA in Political Science and International Relations from the University of California, San Diego.

Max Reads Application Note